Cargando…

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Glioma is the most malignant primary tumor of the central nervous system and is characterized by an extremely low overall survival. Recent breakthroughs in cancer therapy using immune checkpoint blockade have attracted significant attention. However, despite representing the most promising (immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Yangzhi, Liu, Baohui, Sun, Qian, Xiong, Xiaoxing, Chen, Qianxue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729019/ https://www.ncbi.nlm.nih.gov/pubmed/33329549 http://dx.doi.org/10.3389/fimmu.2020.578877

Ejemplares similares

Circulating Tumor Cells for Glioma
por: Zhang, Huikai, et al.
Publicado: (2021)

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
por: Yu, Lu, et al.
Publicado: (2022)

Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment
por: Xu, Yang, et al.
Publicado: (2021)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
por: Zhu, Hua, et al.
Publicado: (2022)

RND2 attenuates apoptosis and autophagy in glioblastoma cells by targeting the p38 MAPK signalling pathway
por: Xu, Yang, et al.
Publicado: (2020)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2019)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

Bioinformatic Profiling of Prognosis-Related Genes in Malignant Glioma Microenvironment
por: Li, Yong, et al.
Publicado: (2020)

Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma
por: Li, Yong, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma
por: Sun, Qian, et al.
Publicado: (2022)

Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma
por: Li, Yong, et al.
Publicado: (2020)

New trends in brain tumor immunity with the opportunities of lymph nodes targeted drug delivery
por: Qi, Yangzhi, et al.
Publicado: (2023)

The Involvement and Therapy Target of Immune Cells After Ischemic Stroke
por: Jian, Zhihong, et al.
Publicado: (2019)

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
por: Zeng, Zhirui, et al.
Publicado: (2022)

Glioma Stem Cell-Targeted Dendritic Cells as a Tumor Vaccine Against Malignant Glioma
por: Ji, Baowei, et al.
Publicado: (2013)

Targeting immune checkpoints in malignant glioma
por: Zhang, Xuhao, et al.
Publicado: (2016)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Prognostic value of γ‐aminobutyric acidergic synapse-associated signature for lower-grade gliomas
por: Jiang, Hongxiang, et al.
Publicado: (2022)

Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2017)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
por: Paluch, Christopher, et al.
Publicado: (2018)

Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
por: D’Amico, Silvia, et al.
Publicado: (2022)

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
por: Zeller, Tobias, et al.
Publicado: (2023)

High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma
por: Yu, Kai, et al.
Publicado: (2022)

Identifying circulating glioma cells and their clusters as diagnostic markers by a novel detection platform
por: Qi, Yangzhi, et al.
Publicado: (2021)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Identification of differentially expressed key genes between glioblastoma and low-grade glioma by bioinformatics analysis
por: Xu, Yang, et al.
Publicado: (2019)

Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis
por: Zhang, Li, et al.
Publicado: (2021)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
por: Zhang, Qi-jie, et al.
Publicado: (2021)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
por: Zemek, Rachael M., et al.
Publicado: (2020)

A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma
por: Luo, Cheng, et al.
Publicado: (2022)

Editorial: Immune Response to Cerebral Ischemia: Exploring Mechanisms and Potential Treatment Targets
por: Ye, YingZe, et al.
Publicado: (2021)

Notch intracellular domain regulates glioblastoma proliferation through the Notch1 signaling pathway
por: Wang, Yixuan, et al.
Publicado: (2021)

Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination
por: Reens, Abigail L., et al.
Publicado: (2021)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
por: Gao, Yuan, et al.
Publicado: (2022)

Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma
por: Cai, Jiayang, et al.
Publicado: (2022)

Targeting Immune Checkpoint Molecules to Eliminate Latent HIV
por: Boyer, Zoe, et al.
Publicado: (2018)

Origin, activation, and targeted therapy of glioma-associated macrophages
por: Xu, Can, et al.
Publicado: (2022)

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
por: Liu, Zefan, et al.
Publicado: (2022)

Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
por: Li, Xueyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l6qti89l3ftrtp3hdfnedm8pm2